



NEWS RELEASE

**PALADIN TO PRESENT AT THE UBS GLOBAL LIFE SCIENCE
CONFERENCE IN NEW YORK**

Montreal, Canada, September 19, 2007 - Paladin Labs Inc. (TSX : PLB), a leading Canadian specialty pharmaceutical company, today announced that Jonathan Goodman, President and CEO will present a corporate update at the 2008 UBS Global Life Science Conference on Thursday September 25th, 2008, at 2:30 p.m. ET, at the Grand Hyatt New York. A copy of the presentation will be available at www.paladinlabs.com.

About Paladin Labs Inc.

Paladin Labs Inc., headquartered in Montreal, Canada, is a leading specialty pharmaceutical company focused on developing, acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. Paladin's shares trade on the Toronto Stock Exchange under the symbol *PLB*. For more information about Paladin, please visit the Paladin Web Site at www.paladinlabs.com.

This news release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiaries may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report as well as in the Company's Annual Information Form for the year ended December 31, 2007. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether a result of new information, future events, or except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company's ongoing quarterly filings, annual report and Annual Information Form and other filings found on SEDAR at www.sedar.com.

For further information please contact:

Paladin Labs Inc.

Samira Sakhia, Chief Financial Officer

Tel: 514-340-5067

Fax: 514-344-4675

e-mail: info@paladin-labs.com

Web Site: www.paladinlabs.com